Skip to content

Medical-device intelligence

LAT: Radioimmunoassay, Cannabinoid(S)

FDA product code LAT: Radioimmunoassay, Cannabinoid(S). View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
LAT
FDA device name
Radioimmunoassay, Cannabinoid(S)
Device class
2
Regulation number
862.3870
Medical specialty
Clinical Toxicology
Review panel
TX

The source does not provide a definition for this entry. Consult the FDA classification and regulation reference for further detail.

Explore clinical toxicology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

16 clearance records and 0 recall records in the covered releases, across 7 source company names and 1 product codes. Dated history runs from Oct 3, 1978 to May 3, 2002.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

Code and FDA device nameClearancesRecalls
LAT · Radioimmunoassay, Cannabinoid(S)160

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

16 matching records
Device / recordCompany in FDA recordSourceSource date
PSYCHEMEDICS RIA CANNABINOID ASSAYK011426 · LATPsychemedics Corp.510(k)May 3, 2002FDA decision date
ABISCREEN ONLINE FOR CANNABINOIDS - ES 50/100K961620 · LATRoche Diagnostic Systems, Inc.510(k)Jun 13, 1996FDA decision date
SUDORMED SWEAT PATCH SPECIMEN CONTAINER FOR COLLECTION OF MARIJUANA IN PERSPIRATIONK936135 · LATSudormed, Inc.510(k)Jun 10, 1996FDA decision date
DOUBLE ANTIBODY CANNABIONOIDS/QUAIL DETER IN URINEK914507 · LATDiagnostic Products Corp.510(k)Dec 18, 1991FDA decision date
ABUSCREEN(R) ONLINE(TM) FOR THC(50/100)(100TEST KTK913414 · LATRoche Diagnostic Systems, Inc.510(k)Sep 25, 1991FDA decision date
URINE THC DIRECT RIA KIT (I-125)K913865 · LATImmunalysis Corporation510(k)Sep 18, 1991FDA decision date
ABUSCREEN ONLINE FOR THC (50 AND 100)K912574 · LATRoche Diagnostic Systems, Inc.510(k)Aug 12, 1991FDA decision date
ABUSCREEN ONLINE TM FOR THCK904996 · LATRoche Diagnostic Systems, Inc.510(k)Jan 11, 1991FDA decision date
ORAL THC-CANNABINOIDS DIRECT RIA KITK843534 · LATImmunalysis Corporation510(k)Oct 30, 1984FDA decision date
URINE THC CANNABINOIDS DIRECT RIA KITK833911 · LATImmunalysis Corporation510(k)Jan 24, 1984FDA decision date
ORAL THC-CANNABINOIDS DIRECT RIA KITK821965 · LATImmunalysis Corporation510(k)Jul 20, 1982FDA decision date
THC-CANNABINOIDS DIRECT URINE RIA KITK820903 · LATImmunalysis Corporation510(k)May 5, 1982FDA decision date
ABUSCREEN RADIOIMMUNOASSAY FOR CANNABIK820391 · LATHoffmann-La Roche, Inc.510(k)Mar 8, 1982FDA decision date
EMIT -D.A.U. CANNABINOID URINE ASSAYK800246 · LATSyva Co.510(k)Feb 26, 1980FDA decision date
TETRAHYDROCANNALBINOL DIRECT BLOOD KITK791649 · LATImmunalysis Corporation510(k)Oct 11, 1979FDA decision date
THC DIRECT RIA KITK781048 · LATImmunalysis Corporation510(k)Oct 3, 1978FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗